GSK1838705A

Research use only, not for human use.

GSK1838705A is a potent, specific inhibitor of IGF-IR and insulin receptor (IR) with IC50 of 2.0 and 1.6 nM.

GSK1838705A is a potent, specific inhibitor of IGF-IR and insulin receptor (IR) with IC50 of 2.0 and 1.6 nM, also is a potent inhibitor of ALK with IC50 of 0.5 nM; display excellent kinase selectivity on a panel of 224 unique protein kinases with only 7 additional kinases to be inhibited by >50% at 0.3 uM; inhibits a panel of cell lines derived from solid and hematologic tumors with IC50 of 20 nM-8 uM (NCI-H929 IC50=197 nM); causes complete regression of ALK-dependent tumors, retards the growth of human tumor xenografts in vivo with minimal effects on glucose homeostasis.

——

——

GSK 1838705A | GSK-1838705A

Angiogenesis

ALK

ALK|IGF-1R|InsulinReceptor|JNK3|RSK1

Cancer

——

1116235-97-2

532.5693

C27H29FN8O3

>98% (HPLC)

10 mM in DMSO

O=C(NC)C1=C(F)C=CC=C1NC2=C3C(NC=C3)=NC(NC4=CC5=C(C=C4OC)CCN5C(CN(C)C)=O)=N2

Benzamide, 2-[[2-[[1-[2-(dimethylamino)acetyl]-2,3-dihydro-5-methoxy-1H-indol-6-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]-6-fluoro-N-methyl-

(-20℃)

With Ice Pack

≥ 2 years